Shibata-Hamaguchi A, Samuraki M, Furui E, Iwasa K, Yoshikawa H, Hayashi S, Yamada M
Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa, Japan.
Acta Neurol Scand. 2007 Dec;116(6):406-8. doi: 10.1111/j.1600-0404.2007.00877.x.
Anti-muscle-specific receptor tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) patients show various responses to conventional immunosuppressive treatment and some patients are resistant to these therapies. We report a 50-year-old Japanese man with anti-MuSK antibody-positive MG, who showed no or poor response to various therapies, including plasmapheresis, corticosteroid, and tacrolimus. The patient was then treated with intravenous immunoglobulin (IVIG), and showed a good response that persisted over 20 months. The outcome of this case suggests that IVIG treatment may be an effective therapeutic option for anti-MuSK antibody-positive MG, with a potentially long-term effect.
抗肌肉特异性受体酪氨酸激酶（MuSK）抗体阳性的重症肌无力（MG）患者对传统免疫抑制治疗表现出不同反应，一些患者对这些疗法耐药。我们报告了一名50岁的日本男性抗MuSK抗体阳性MG患者，他对包括血浆置换、皮质类固醇和他克莫司在内的各种疗法无反应或反应不佳。该患者随后接受静脉注射免疫球蛋白（IVIG）治疗，并表现出良好反应，且持续超过20个月。该病例结果表明，IVIG治疗可能是抗MuSK抗体阳性MG的一种有效治疗选择，且可能具有长期效果。
Zotero 插件